Levetiracetam Actavis Group

Levetiracetam Actavis Group is an epilepsy medicine. It can be used on its own in patients from 16 years of age with newly diagnosed epilepsy, to treat partial-onset seizures (fits) with or without secondary generalisation. This is a type of epilepsy where too much electrical activity in one side of the brain causes symptoms such as sudden, jerky movements of one part of the body, distorted hearing, sense of smell or vision, numbness, or a sudden sense of fear. Secondary generalisation occurs when the overactivity later reaches the whole brain. Levetiracetam Actavis Group can also be used as an add-on to other anti-epileptic medicines to treat: - partial-onset seizures with or without generalisation in patients from one month of age; - myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in patients from 12 years of age with juvenile myoclonic epilepsy; - primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause). Levetiracetam Actavis Group contains the active substance levetiracetam and is a ‘generic medicine’. This means that Levetiracetam Actavis Group contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Keppra.